Terns Pharmaceuticals, (id:7888 TERN)
5.79 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 10:56:06 AM)
Exchange closed, opens in 22 hours 33 minutes
About Terns Pharmaceuticals,
Market Capitalization 484.15M
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
| Headquarters (address) |
1065 East Hillsdale Boulevard Foster City 94404 CA United States |
| Phone | 650 525 5535 |
| Website | https://www.ternspharma.com |
| Employees | 66 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | TERN |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 3.68 - 11.40 |
| Market Capitalization | 484.15M |
| P/E trailing | -4.56 |
| P/E forward | -4.10 |
| Price/Book | 1.33 |
| Beta | -0.334 |
| EPS | -1.18 |
| EPS United States (ID:6, base:3402) | 24.22 |